Thymoma and Thymic Carcinoma Treatment — Procedure Guide, Recovery & Risks | MyMedicPlus

Thymoma and thymic carcinoma are the most common primary tumours of the anterior mediastinum, arising from the epithelial cells of the thymus gland. Thymoma accounts for approximately 20% of all mediastinal tumours and has variable malignant potential. The WHO classifies thymoma into types A, AB, B1, B2, and B3, with increasing epithelial cell content and more aggressive behaviour toward type B3. Thymic carcinoma (formerly type C) is a frankly malignant tumour with high metastatic potential and worse prognosis than thymoma. Up to 50% of thymoma patients have an associated autoimmune condition, most commonly myasthenia gravis (MG). Total thymectomy is the cornerstone of treatment for resectable disease.

Thymoma is classified by the World Health Organisation (WHO 2004/2015) into types A, AB, B1, B2, B3, and thymic carcinoma, with prognostic significance: Type A and AB have excellent prognosis; Type B3 and thymic carcinoma are more aggressive. Staging uses the Masaoka-Koga system: Stage I (encapsulated, no invasion), Stage II (microscopic or macroscopic capsular invasion), Stage III (invasion of adjacent organs), Stage IV (pleural or pericardial dissemination, or haematogenous metastases). Associated paraneoplastic syndromes are present in 30–50% of thymoma patients: myasthenia gravis (most common, 30%), pure red cell aplasia (5%), and hypogammaglobulinaemia (5%).

Surgical thymectomy is indicated for all patients with resectable thymoma (Masaoka-Koga stages I-IIB) and good performance status. Thymectomy is also indicated for myasthenia gravis patients with or without thymoma, as resection reduces acetylcholine receptor antibody titres and can improve or resolve MG in 30-60% of patients within 3-5 years. Unresectable stage III-IV thymoma and thymic carcinoma are managed with platinum-based chemotherapy (cisplatin, doxorubicin, cyclophosphamide — CAP protocol) followed by re-evaluation for resectability and adjuvant radiotherapy. A multidisciplinary thoracic oncology team review is required for all cases.

For myasthenia gravis without thymoma, thymectomy is now standard of care based on the MGTX trial (2016 NEJM) — the first randomised controlled trial demonstrating that thymectomy plus prednisone achieves significantly better 3-year outcomes (minimal manifestation status) than prednisone alone, with reduced steroid dose requirements and hospitalisation rates. Patients with thymic carcinoma require multimodal treatment: surgery for resectable disease, platinum-based chemotherapy (cisplatin-etoposide, CAP regimen) for advanced disease, and checkpoint inhibitor immunotherapy (pembrolizumab) for PD-L1-positive cases.

Extended transsternal thymectomy (median sternotomy) provides the best visualisation and access for complete en bloc resection of the thymus and all anterior mediastinal fat, which may contain ectopic thymic tissue critical to MG treatment. Video-assisted thoracoscopic surgery (VATS) or robotic thymectomy via bilateral or unilateral approach is increasingly used for smaller, early-stage tumours and offers equivalent oncological outcomes with reduced post-operative pain and shorter hospital stay. Surgery involves careful dissection of the thymus from the superior vena cava, innominate vein, pericardium, and phrenic nerves, which must be identified and preserved. Cardiopulmonary bypass is rarely required except for tumour invading the great vessels.

For VATS (video-assisted thoracoscopic) thymectomy, three ports are placed in the intercostal spaces; CO2 insufflation is used to improve visualisation. The thymus and all mediastinal fat is dissected from the pericardium, pleural surfaces, phrenic nerve, and innominate vein using energy devices (Harmonic scalpel). The specimen is extracted in an endobag. A single chest drain is placed through one port site and removed within 48 hours. For large tumours (greater than 5 cm), median sternotomy provides superior exposure and control. The phrenic nerve is identified and preserved bilaterally throughout the dissection, running over the pericardium lateral to the thymic tissue. Frozen section pathology may be requested intraoperatively to assess resection margins.

Complete surgical resection (R0) achieves 5-year survival of 95%+ for Masaoka-Koga stage I thymoma and 85-90% for stage II. Stage III disease treated with complete resection plus adjuvant radiotherapy achieves 5-year survival of 60-70%. In myasthenia gravis patients with thymoma, thymectomy reduces acetylcholine receptor antibody titres and achieves complete stable remission (no symptoms or medication required) in 20-30% and significant clinical improvement in 60-70% within 3-5 years. Early diagnosis and complete resection significantly improve long-term outcomes for all thymic tumour types.

For myasthenia gravis, the MGTX trial demonstrated that extended transsternal thymectomy achieved minimal manifestation status (MMS — symptoms controlled on low-dose prednisone) in 67% of patients at 3 years compared to 47% in the prednisone-only group. Thymectomy-treated patients required significantly lower average prednisone doses (44 mg vs 60 mg alternate-day) and had fewer hospitalisations. Long-term immunological benefit of thymectomy in MG continues to accrue over years, reflecting the role of the thymus in maintaining autoreactive T-cell populations.

Phrenic nerve injury causing ipsilateral diaphragm paralysis occurs in 2-5% of cases and may cause dyspnoea, particularly in patients with pre-existing respiratory compromise. Bleeding from the innominate vein or superior vena cava is the most dangerous intra-operative complication. Post-operative complications include pleural effusion requiring drainage (10-20%), wound infection, and pneumonia. Myasthenic crisis — severe exacerbation of MG requiring mechanical ventilation — may be precipitated by the stress of surgery in patients with pre-existing MG and requires specialist neurological support peri-operatively with plasmapheresis or IVIG preparation. Incomplete resection significantly worsens prognosis and is associated with high recurrence rates.

Superior vena cava (SVC) injury — from tumours abutting or invading the SVC — is the most dangerous intraoperative complication, requiring immediate vascular repair. Pleural effusion and chylothorax from thoracic duct injury require drainage and dietary management. Myasthenic crisis — acute respiratory failure from cholinergic blockade worsening post-operatively — occurs in 5–10% of MG thymectomy patients and requires ICU admission, ventilatory support, and plasma exchange or IVIg.

Hospital stay is typically 5-10 days. Chest drains are removed after 2-3 days when drainage is minimal. Respiratory physiotherapy is initiated immediately post-operatively to prevent atelectasis and pneumonia. MG patients require continued neurological monitoring and immunosuppression management post-operatively, with neurologist involvement. Return to normal activities occurs at 4-6 weeks. Adjuvant radiotherapy (45-50 Gy) is recommended for incompletely resected (R1-R2), stage III, or B3 thymomas and is delivered over 5 weeks starting 4-6 weeks after surgery. Long-term oncology surveillance with CT chest every 6 months for 5 years then annually is required, given the potential for late recurrence 10-15 years after initial treatment.

Patients receiving adjuvant radiotherapy begin treatment at 4–6 weeks post-operatively to the anterior mediastinum, particularly for stage II-III thymoma. Long-term follow-up with annual CT chest for 10+ years is essential given the propensity for late thymoma recurrence (5–20 years post-resection for stage I-II disease). Surveillance for paraneoplastic syndromes associated with thymoma (myasthenia gravis, pure red cell aplasia, hypogammaglobulinaemia) continues lifelong.